Skip to main content

Abbott Laboratories statistics

  • ABT · NYSE
  • Pharmaceuticals
  • Health Care Equipment
  • S&P 500
$108.52+1.18%Close 13 Nov 2026 · Market value $188.1B

Valuation and share-price figures are struck on the latest close (13 Nov 2026); the others are read from the company's reports. A figure that cannot be worked out, such as a P/E after a loss, is left out.

Valuation

Abbott Laboratories is valued at $188.1B on its latest close. Its price is 40.0 times its earnings.

Market value$188.1B
Enterprise value$215.4B
Price / earnings40.03
Price / sales3.90
Price / book3.69
EV / EBITDA20.40
EV / sales4.47
Price / free cash flow27.84
Price / free cash flow, own 5-year average29.11
EV / EBIT32.34
EV / free cash flow31.82
Free cash flow yield3.6%
Dividend yield2.3%

Share price

Latest close$108.52
Day's change+1.2%
52-week high$132.03
52-week low$81.97
From 52-week high−17.8%
Return · 1 month+3.5%
Return · 3 months−4.9%
Return · year to date−13.4%
Return · 1 year−15.8%
Beta · 1 year against the S&P 5000.07
50-day average$103.91
200-day average$101.56
RSI 1454.1
Average volume · 20 sessions9.5M

Margins and returns

For fiscal 2025, as filed.

Gross margin56.4%
Operating margin18.2%
Net margin14.7%
Free cash flow margin16.7%
Return on equity13.1%
Return on assets7.4%
Return on invested capital9.9%
Return on invested capital, 5-year average11.4%
Return on capital employed11.7%
Stock-based compensation / revenue1.5%

Financial position

At the end of fiscal 2025.

Cash and equivalents$8.52B
Total debt$14.14B
Net debt$5.20B
Current ratio1.58
Quick ratio0.83
Debt / equity0.27
Net debt / EBITDA0.47
Interest coverage16.33

Growth

Revenue, latest quarter on a year+14.5%
Revenue, twelve months on a year+10.0%
EPS, latest quarter on a year−43.6%
EPS, twelve months on a year−66.1%
Revenue, 5-year compound+5.1%
Revenue, 10-year compound+8.1%
Net income, 5-year compound+7.7%
Free cash flow, 5-year compound+5.3%
EPS, 5-year compound+8.2%

Shares and dividends

For fiscal 2025, as filed.

Diluted shares1.7B
Shares outstanding, 5-year compound−0.4%
Net share repurchases$497.0M
Dividends per share$2.40
Dividend payout63.1%

Taxes

For fiscal 2025, as filed.

Income tax expense$1.94B
Effective tax rate22.9%

ABT in the terminal

Valuation against the company's own history, a cash-flow valuation, peers, charts and alerts.